Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Goserelin (Zoladex) vs PT-141 (Bremelanotide)
An educational, source-based comparison of Goserelin (Zoladex) and PT-141 (Bremelanotide) — how each peptide works, what it's researched for, and what to know before going deeper.
Decapeptide GnRH agonist delivered via biodegradable subcutaneous implant. Suppresses gonadotropin and sex hormone production through pituitary desensitization.
- Prostate cancer
- Breast cancer (premenopausal)
- Endometriosis
- • FDA-approved.
- • Testosterone/estrogen flare; menopausal symptoms.
Melanocortin agonist researched for sexual desire and arousal.
A synthetic analog of α-MSH that activates melanocortin receptors (primarily MC4R) in the central nervous system. Unlike PDE5 inhibitors, it acts on neural pathways governing sexual desire rather than vascular flow.
- Hypoactive sexual desire disorder (FDA-approved as Vyleesi in premenopausal women)
- Male erectile response (research)
- Central arousal pathways
- • FDA-approved (Vyleesi) only for HSDD in premenopausal women.
- • Can cause nausea, flushing, transient blood pressure increases.
- • Avoid in uncontrolled hypertension or cardiovascular disease.
Goserelin (Zoladex) vs PT-141 (Bremelanotide) — Key differences
- Class: Goserelin (Zoladex) is classified as GnRH Agonist · Hormonal, while PT-141 (Bremelanotide) is Sexual Health · Neurologic.
- Primary research focus: Goserelin (Zoladex) — prostate cancer; PT-141 (Bremelanotide) — hypoactive sexual desire disorder (fda-approved as vyleesi in premenopausal women).
- Tag: FDA-Approved · Oncology vs Libido.